We report here that interleukin-3 (IL-3) and erythropoietin (EPO) induce formation of a complex composed of two SH2-containing phosphatases, the tyrosine phosphatase SHP-2 and the SH2 containing inositol 5-phosphatase (SHIP). Both SHP-2 and SHIP are known to be involved in growth factor signal transduction, but their potential interaction in the same pathway is novel. SHIP has previously been shown to associate with SHC, and potentially to be involved in regulating apoptosis. In contrast, in some model systems, SHP-2 has been demonstrated to positively regulate cell growth. Both phosphatases in the complex were tyrosine phosphorylated, and the amount of SHIP coprecipitating with SHP-2 was inversely related to the amount of SHIP coprecipitating with SHC. In hematopoietic cells transformed by the BCR/ABL oncogene, this phosphatase complex was found to be constitutively present with both components heavily tyrosine phosphorylated. Also, other proteins were detected in the complex, including BCR/ABL itself and c-CBL. However, transformation by BCR/ABL was associated with a reduced SHIP protein expression, which could further aect the accumulation of various inositol polyphosphates in these leukemic cells. These data suggest that the function of SHIP and SHP-2 in normal cells are linked and that BCR/ABL alters the function of this signaling complex.
Introduction
The hematopoietic inositol-5 phosphatase SHIP has been recently cloned (Damen et al., 1996; Lioubin et al., 1996) and shown to be transiently tyrosine phosphorylated in response to growth factor receptor activated tyrosine kinases or constitutively phosphorylated by BCR/ABL (Damen et al., 1996; Matsuguchi et al., 1994) . SHIP has speci®c inositol-5-phosphatase activity for phosphatidylinositol 3, 4, 4, 5) P 3 ] and inositol 1,3,4,5-tetraphosphate [Ins(1,2,4,5)P 4 ] and thus generates PtdIns(3,4)P 2 and Ins(1,3,4)P 3 respectively (Damen et al., 1996) . In normal cells, the enzyme activity of SHIP has not been shown to change after receptor activation, suggesting that interaction with other signaling proteins might be important to mediate biological eects (Damen et al., 1996) . SHIP has been shown to interact through its SH2 domain with the adapter protein SHC (Liu et al., 1997a) , which in turn binds through its protein tyrosine binding (PTB) domain to phosphorylated NPXY motifs in SHIP (Kavanaugh et al., 1996; Lioubin et al., 1996) . Another prominent SHIP binding protein is the adapter protein GRB2 that competes with SHIP for SH2 binding to SHC (Liu et al., 1994 (Liu et al., , 1997a or binds to a C-terminal proline rich region in SHIP through its SH3 domains (Damen et al., 1996) . Relocation of SHIP to the cell membrane may be an important regulatory mechanism, and thus transient interaction of SHIP with signaling complexes associated with transmembrane growth factor receptors may be quite important. The biological eects of SHIP and its substrates or products are just beginning to be elucidated. However, recent studies suggest that SHIP negatively regulates growth and might have an important role in apoptosis (Lioubin et al., 1996; Liu et al., 1997a; Ono et al., 1996) . Other molecules which bind to SHIP through its SH2 domain are likely to be important in this process, as deleting the SH2 domain impairs apoptotic activity of SHIP and prevents its tyrosine phosphorylation (Liu et al., 1997a) .
SHP-2 is a tyrosine phosphatase which, like SHIP, is involved in growth factor and oncogene-mediated signaling. SHP-2 and the related tyrosine phosphatase SHP-1 belong to a class of phosphatases containing two adjacent SH2 domains which are important for linking these phosphatases to activated receptors such as the PDGF or EGF receptor (Feng et al., 1993; Lechleider et al., 1993; Vogel et al., 1993) . In PDGF signaling, SHP-2 binds directly to the receptor and recruits GRB2 and SOS to a phosphorylation site in SHP-2, thus providing a potential pathway which contributes to activation of RAS (Bazenet et al., 1996; Klinghoer et al., 1996) . Similarly, in Xenopus laevis, SHP-2 appears to positively regulate early development and is required for MAP kinase activation (Tang et al., 1995) . Also, Corksrew (Crw) an SHP-2 homolog in Drosophila melanogaster, is required for growth factor receptor mediated signaling and loss of function mutations in crw are lethal during development (Perkins et al., 1996) .
In this study, we found that SHIP and SHP-2 coimmunoprecipitate in hematopoietic cell lines. The amount of the complex and the amount of tyrosine phosphorylation of SHIP and SHP-2 are increased by at least two dierent hematopoietic growth factors, interleukin-3 and erythropoietin, and regulated in a dierent way by BCR/ABL. Expression of SHIP tends to be reduced in cell lines transformed by BCR/ABL, but it is heavily tyrosine phosphorylated and forms a constitutive complex with SHP-2, which is also constitutively tyrosine phosphorylated. These data suggest that in normal cells the functions of both of these phosphatases are linked, and in BCR/ABLtransformed cells, the function of this complex of phosphatases may be permanently altered.
Results

IL-3 and EPO increase the association of SHIP with SHP-2 and SHC
Hematopoietic growth factors including IL-3 and EPO induce tyrosine phosphorylation of cellular proteins ( Figure 1a ). Figure 1b (top panel) demonstrates that IL-3 and EPO induce tyrosine phosphorylation of the 145 kDa protein SHIP, which coprecipitated with tyrosine phosphoproteins of 52 kDa and 72 kDa. Also, after EPO, but not IL-3 stimulation, a 40 kDa phosphoprotein coprecipitated with SHIP. The 52 kDa protein was identi®ed as SHC and the 72 kDa proteins as SHP-2 (Figure 1b bottom panels). Inducible association between SHIP and SHC has been described before. Interestingly, there was constitutive association between SHIP and SHP-2 in unstimulated cells although the association between these two proteins increased after growth factor stimulation. These results were con®rmed by immunoprecipitation with anti-SHP-2 followed by immunoblotting with anti-SHIP using lysates of IL-3 or EPO stimulated cells (data not shown). In these experiments we did not detect coprecipitation of SHP-2 with SHC.
SHIP forms complexes with both SHC and SHP-2 in pervanadate treated BaF3 cells
To investigate the potential interaction of SHP-2 with cellular proteins in a situation where tyrosine phosphatases are inactivated, BaF3 cells were treated with pervanadate. Figure 2a demonstrates that pervanadate treatment leads to increased tyrosine phosphorylation of cellular proteins. Pervanadate increases the tyrosine phosphorylation of SHP-2 and increases its association with other signaling proteins ( Figure 2b , right panel). Figure 2b (right panel) demonstrates that SHP-2 inducibly coprecipitates with at least three major tyrosine phosphorylated proteins of approximately 145, 100, and 65 kDa after 20 and 60 min of pervanadate treatment. The 145 kDa band was identi®ed as SHIP. In some experiments SHIP appeared as a doublet of 145 kDa and 140, which may represent isoforms of SHIP, as the antibody used in these experiments is known to recognize dierent isoforms. Interestingly, after pervanadate treatment SHIP and its isoforms also associated with SHP-2 ( Figure 2b , bottom panels). SHIP itself was also found to be tyrosine phosphorylated after pervanadate treatment and to coprecipitate with tyrosine phos- In control experiments the quality of the SHIP antiserum to speci®cally recognize SHIP in SHC immunoprecipitates of BaF3 cells was tested. SHC was found to be tyrosine phosphorylated after pervanadate treatment and to coprecipitate with SHIP. Also, preimmune rabbit serum did not precipitate SHIP, SHP-2 or SHC proteins (Figure 2c ). SHC and SHP-2 were not found to coprecipitate, suggesting that they are likely to be in dierent complexes (Figure 2b , bottom right panel). These data suggest that inhibition of tyrosine phosphatases by pervanadate, which would include inhibition of SHP-2, induces tyrosine phosphorylation of SHIP, SHC and SHP-2 and also alters the composition of SHIP-containing complexes in Ba/F3 cells. (Figure 3b, top panel) . Again, SHIP and SHP-2 were found to coprecipitate in BaF3 cells. This complex was not increased in BaF3/p210 cells but coprecipitation was still detected despite the reduced expression of SHIP (Figure 3b, bottom panels) . However, coprecipitation of a tyrosine phosphorylated 72 kDa band in SHIP immunoprecipitations could only be observed after long exposure of the immunoblot. The sustained interaction between SHIP and SHP-2 is likely to be in part due to increased SHP-2 phosphorylation, since the SH2 domain of ABL and SHIP can precipitate SHP-2 in BCR/ABL transformed but not in normal cells (data not shown). In all three immunoprecipitations the 210 kDa protein was identi®ed as BCR/ABL and the 120 kDa protein as c-CBL (Figure 3b, bottom panels) . We also found a small amount of SHIP coprecipitating with SHP-2 using lysates of the Philadelphia chromosome positive cell lines BV173 and K562 (data not shown). These data suggest that in BCR/ABL transformed cells, in contrast to IL-3 and EPO stimulated cells, the formation of the SHIP/SHP-2 complex is small and possibly insignificant.
Discussion
In this report, we demonstrate by coimmunoprecipitation the presence of protein complexes that contain SHP-2 and SHIP in untransformed hematopoietic cell lines. This interaction is increased considerably following stimulation with IL-3 and EPO, which also induce tyrosine phosphorylation of both phosphatases. In BCR/ABL transformed cells, this complex is altered and the phosphatase complex coprecipitates with BCR/ ABL itself, and with another signaling protein previously linked to BCR/ABL transformation, c-CBL. Since both SHP-2 and SHIP are believed to have important signaling roles related to proliferation and viability, these results overall suggest that the functions of these two phosphatases are linked.
The nature of the interaction of SHIP and SHP-2 may be quite complex. In untransformed cell lines, a small amount of SHP-2 was found to be preassociated with SHIP when neither protein was signi®cantly tyrosine phosphorylated. After growth factor stimulation, both phosphatases in this complex are tyrosine phosphorylated, and it is likely that the overall increase in the complex is mediated through SH2 binding. In fact, during preparation of this manuscript, Liu et al. reported that after IL-3 stimulation the SHIP SH2 domain can inducibly bind directly to a phosphotyrosine residue in SHC or SHP-2 (Liu et al., 1997b) . In pervanadate treated and growth factor stimulated cells we were unable to detect coprecipitation of SHC and SHP-2 suggesting that SHIP can bind to either SHC or SHP-2, but not to both at the same time. Also, increased binding of SHIP to SHC correlated with decreased binding to SHP-2, suggesting that SHC and SHP-2 may in fact compete for binding to SHIP.
In BCR/ABL expressing cells the interactions are more complex and other proteins are contained with this phosphatase complex, such as c-CBL and BCR/ ABL. Since each of the proteins in the phosphatase Onc consequence of the interaction between SHIP and SHP-2 is likely to be altered enzyme activity of either or both enzymes. This is of special interest since SHIP has previously been reported to be important in regulating apoptosis (Lioubin et al., 1996; Liu et al., 1997a; Ono et al., 1996) . In primary hematopoetic cells, growth factors such as IL-3 and EPO are required to maintain viability, and one of the prominent biological eects of BCR/ABL in primary CML cells is inhibition of apoptosis (Bedi et al., 1994; Sattler and Salgia, 1997) . It will be of considerable interest to examine the role of SHIP in the altered regulation of viability that is characteristic of chronic myeloid leukemia cells.
It is possible that one function of SHP-2 in this complex is to dephosphorylate SHIP, possibly reducing its accumulation at the cell membrane. If so, SHP-2 would then reduce the activity of an enzyme which may negatively regulate apoptosis. An alternative model would be that the enzymatic activity of SHIP is directly regulated by one or more tyrosine phosphorylation events. Finally, it is also possible that SHIP is not a substrate for SHP-2, but that they function in the same signaling pathway. In any event, the ®nding that these two phosphatases exist in a complex suggests that their functions are interrelated in a manner which will be of considerable interest to decipher.
The role of this phosphatase complex in BCR/ABL transformation is also of interest. Constitutive activation of the Pl3K pathway by BCR/ABL has drawn special attention, since there is increasing evidence that Pl3K is important in transformation by BCR/ABL. Inhibition of Pl3K by the inhibitor wortmannin, a speci®c inhibitor of the p110 subunit of Pl3K, inhibits proliferation of BCR/ABL transformed cells (Skorski et al., 1995) . We recently described a complex containing Pl3K, c-CBL, and BCR/ABL (Sattler and Salgia, 1997; Sattler et al., 1996) . Constitutive binding of Pl3K to tyrosine phosphorylated c-CBL is a possible mechanism of Pl3K activation and might contribute to BCR/ABLmediated transformation. The major in vivo substrates of Pl3K are PtdIns(4)P or PtdIns(4.5)P 2 , which are converted by Pl3K to PtdIns(3.4)P 2 or PtdIns(3,4,5)P 3 (Divecha and Irvine, 1995) . PtdIns(3,4)P 2 or PtdIns(3,4,5)P 3 are elevated in BCR/ABL transformed cells or after growth factor stimulation and one or both could have multiple activities related to viability, motility and other biological events. One possibility is that the SHIP activity is reduced in cells transformed by BCR/ABL, either by phosphorylation, sequestration with BCR/ABL, or reduced expression. This would lead to increased levels of 5-phosphate lipids, and possibly to increased viability and other eects. It is intriguing that we observed reduced expression of SHIP in BCR/ABL transformed cell lines (compared to their untransformed counterparts). At the present time, we do not know if this is due to reduced protein production or accelerated destruction or both. This would suggest, at least in cell lines, that transformation by BCR/ABL is facilitated by having reduced SHIP activity, thus favoring a model in which increased SHIP activity leads to decreased viability. It will be of interest to determine the cellular localization of SHIP in BCR/ABL transformed cells and to directly look for deregulation of SHIP or SHP-2 activity in these cells.
Materials and methods
